drugset / Trial / NCT04655040

Estimation of the Effect of Multiple Dose Ritlecitinib (PF-06651600) on the Pharmacokinetics of a Single Dose of Caffeine in Healthy Participants

NCT04655040

Phase 1 Completed 12 enrolled Pfizer
NaSingle-groupOpen-labelBasic science

Summary

This will be a Phase 1, 2 period, fixed sequence, multiple-dose, open-label study of the effect of ritlecitinib on caffeine PK in healthy participants. Approximately 12 healthy male and/or female participants will be enrolled in the study.

Timeline

Start
2020-12-18
Primary completion
2021-03-05
Completion
2021-03-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Caffeine Small molecule 100 mg Oral
Subject Ritlecitinib Small molecule 200 mg Oral

Indications

No indication recorded.